Intrathecal liposomal cytarabine in children under 4 years with malignant brain tumors

2009 ◽  
Vol 95 (1) ◽  
pp. 65-69 ◽  
Author(s):  
Alvaro Lassaletta ◽  
Blanca Lopez-Ibor ◽  
Elena Mateos ◽  
Marta Gonzalez-Vicent ◽  
Antonio Perez-Martinez ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Liposomal Cytarabine ◽  
Malignant Brain Tumors

scholarly journals BMET-08. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE IS FEASIBLE AND SAFE: EXPERIENCE IN 57 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS

2016 ◽  
Vol 18 (suppl_6) ◽  
pp. vi27-vi28 ◽  
Author(s):  
Irene Slavc ◽  
Andreas Peyrl ◽  
Amedeo A. Azizi ◽  
Johannes Gojo ◽  
Dominik Reisinger ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Children And Adolescents ◽  
Liposomal Cytarabine ◽  
Malignant Brain Tumors

scholarly journals DDEL-03. LONG-TERM INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE AND LIPOSOMAL CYTARABINE: EXPERIENCE IN 75 CHILDREN AND ADOLESCENTS WITH MALIGNANT BRAIN TUMORS

2020 ◽  
Vol 22 (Supplement_3) ◽  
pp. iii284-iii284
Author(s):  
Natalia Stepien ◽  
Andreas Peyrl ◽  
Amedeo Azizi ◽  
Johannes Gojo ◽  
Lisa Mayr ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Tumor Cells ◽  
Slow Release ◽  
Intrathecal Therapy ◽  
Liposomal Cytarabine ◽  
Release Formulation ◽  
Malignant Brain Tumors ◽  
Slow Release Formulation ◽  
Anti Cancer

Abstract BACKGROUND Malignant brain tumors of childhood carry a high risk for leptomeningeal dissemination and tumor cells floating in the CSF are often not amenable to systemic and/or antiangiogenic chemotherapy. We report on our experience with an intraventricular therapy consisting of alternating cycles of liposomal cytarabine and etoposide. PATIENTS AND METHODS Between 2004 and 2017, 75 patients aged 0.6 to 22 years (median 11) with various malignant brain tumors received intraventricular etoposide 0.25mg (<1year) - 0.5mg on five consecutive days alternating with liposomal cytarabine at a dose of 25mg (<3 years) - 50mg via an Ommaya reservoir. RESULTS 5533 doses of etoposide (5–277/patient, median 141) corresponding to 1–56 five-day-cycles/patient alternating with 534 doses of liposomal cytarabine (1–21/patient, median 11) were administered. Treatment was given over a period of 1 – 146 months (median 73.5). Toxicities did occur but were infrequent and mostly mild. Since all patients received some sort of concurrent anti-cancer therapy, the efficacy of intrathecal therapy cannot be assessed independently. However, 29/75 patients are still alive, and none of the patients had tumor cells in the CSF at their last evaluation. CONCLUSION In conclusion, alternating intraventricular liposomal cytarabine and etoposide produced responses and proved to be an important adjunct for patients receiving drugs with a low penetrance into the CSF. Since production of liposomal cytarabine was discontinued in 2017 it remains to be determined whether substitution of the slow release formulation by aqueous cytarabine on days 1, 4, 8, and 11 may produce similar results.

Deleted in Malignant Brain Tumors 1 (DMBT1) is differentially expressed in cholangiocarcinogenesis and shows influence on patient survival

2014 ◽  
Vol 52 (01) ◽  
Author(s):  
B Goeppert ◽  
L Frauenschuh ◽  
M Zucknick ◽  
S Roessler ◽  
A Stenzinger ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Patient Survival ◽  
Differentially Expressed ◽  
Malignant Brain Tumors

LOCAL HYPERTHERMIA IN TREATMENT FOR MALIGNANT BRAIN TUMORS

2018 ◽  
Vol 64 (1) ◽  
pp. 54-61
Author(s):  
A. Ryabova ◽  
O. Gribova ◽  
V. Novikov ◽  
E. Choinzonov ◽  
Zh. Starceva ◽  
...  
Keyword(s):  
Experimental Data ◽  
Radiation Therapy ◽  
Brain Tumors ◽  
Tumor Cells ◽  
Combined Treatment ◽  
Complex Treatment ◽  
Local Hyperthermia ◽  
Malignant Brain Tumors ◽  
Sensitizing Effect ◽  
Methods Of Treatment

Unsatisfactory results of complex treatment for malignant brain tumors stimulate search of new effective methods of treatment. Radiation therapy is an integral part of the combined treatment but often does not influence lethally on resistant tumor cells. Thereby in recent decades there has been an active search for different modifiers, which can increase the sensitivity of tumors to chemotherapy and radiotherapy. One of the universal sensitizers is the local hyperthermia. Experimental data showed that the effect of high temperatures had both a direct damaging effect on tumor cells and a sensitizing effect. The literature review given in the article provides an overview of the existing methods of the local hyperthermia for brain tumors treatment.

scholarly journals The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals

2021 ◽  
Vol 22 (9) ◽  
pp. 4629
Author(s):  
Cristina Carrato ◽  
Carolina Sanz ◽  
Ana María Muñoz-Mármol ◽  
Ignacio Blanco ◽  
Marta Pineda ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Mismatch Repair ◽  
Rare Event ◽  
Deficiency Syndrome ◽  
Mismatch Repair Deficiency ◽  
Malignant Brain Tumors ◽  
Repair Deficiency ◽  
Clinical Awareness ◽  
High Degree ◽  
Constitutional Mismatch Repair Deficiency

Biallelic germline mismatch repair (MMR) gene (MLH1, MSH2, MSH6, and PMS2) mutations are an extremely rare event that causes constitutional mismatch repair deficiency (CMMRD) syndrome. CMMRD is underdiagnosed and often debuts with pediatric malignant brain tumors. A high degree of clinical awareness of the CMMRD phenotype is needed to identify new cases. Immunohistochemical (IHC) assessment of MMR protein expression and analysis of microsatellite instability (MSI) are the first tools with which to initiate the study of this syndrome in solid malignancies. MMR IHC shows a hallmark pattern with absence of staining in both neoplastic and non-neoplastic cells for the biallelic mutated gene. However, MSI often fails in brain malignancies. The aim of this report is to draw attention to the peculiar IHC profile that characterizes CMMRD syndrome and to review the difficulties in reaching an accurate diagnosis by describing the case of two siblings with biallelic MSH6 germline mutations and brain tumors. Given the difficulties involved in early diagnosis of CMMRD we propose the use of the IHC of MMR proteins in all malignant brain tumors diagnosed in individuals younger than 25 years-old to facilitate the diagnosis of CMMRD and to select those neoplasms that will benefit from immunotherapy treatment.

scholarly journals Cytogenetic landscape of paired neurospheres and traditional monolayer cultures in pediatric malignant brain tumors

2014 ◽  
Vol 17 (7) ◽  
pp. 965-977 ◽  
Author(s):  
Xiumei Zhao ◽  
Yi-Jue Zhao ◽  
Qi Lin ◽  
Litian Yu ◽  
Zhigang Liu ◽  
...  
Keyword(s):  
Brain Tumors ◽  
Malignant Brain Tumors ◽  
Monolayer Cultures
Sign in / Sign up

Export Citation Format

Share Document